← Back to Screener
Generate Biomedicines, Inc. Common Stock (GENB)
Price$12.87
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (4W)-5.77%
VGM Score87.41
Market Capitalization$1.89B
All Metrics
Book Value / Share (Quarterly)$4.02
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-5.78%
10-Day Avg Trading Volume1.01M
EPS (Annual)$-1.59
ROI (Annual)-100.04%
Cash / Share (Quarterly)$4.03
ROA (Last FY)-61.53%
Cash Flow / Share (Annual)$-1.60
P/B Ratio3.68x
P/B Ratio (Quarterly)3.09x
Net Income / Employee (Annual)$-651,100
EPS Incl Extra (Annual)$-1.59
Current Ratio (Annual)2.85x
Quick Ratio (Quarterly)8.85x
3-Month Avg Trading Volume0.67M
P/S Ratio (Annual)59.36x
Asset Turnover (Annual)0.10x
52-Week High$16.75
EPS Excl Extra (Annual)$-1.59
Quick Ratio (Annual)2.70x
13-Week Price Return3.37%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)9.17x
Enterprise Value$1.74B
Revenue / Employee (Annual)$102,200
Pretax Margin (Annual)-698.59%
Cash / Share (Annual)$1.74
3-Month Return Std Dev99.85%
ROE (Last FY)-103.72%
EPS Basic Excl Extra (Annual)$-1.59
Total Debt / Equity (Quarterly)0.01x
Revenue / Share (Annual)$0.25
Year-to-Date Return1.74%
5-Day Price Return-0.77%
EPS Normalized (Annual)$-1.59
Net Profit Margin (Annual)-636.99%
Month-to-Date Return-1.91%
EBITD / Share (Annual)$-1.74
Operating Margin (Annual)-737.04%
Price vs S&P 500 (13W)-4.88%
Beta0.90x
52-Week Low$11.00
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-1.06est. -0.51
Analyst Recommendations
Apr 2026
May 2026
4.13
4.09
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. Common Stock | — | — | A | $12.87 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Generate Biomedicines is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to design novel protein therapeutics. Its proprietary Generate Platform enables rapid drug discovery and development across multiple therapeutic modalities. The company's pipeline includes three clinical candidates: GB-0895, GB-4362, and GB-5267.